Spinal Simplicity, LLC
$40.8M 4,988 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH reported $41,126,339.13 across General Payments, Research, and Ownership to 2,203 physicians and teaching hospitals across 4,047 transactions.
- $41.1M Top 10% payer
- All-tracks total
- 4,047 Top quartile volume
- Transactions
- 2,203 Top quartile reach
- Recipients
- −$366.1K
- General Payments vs PY2023
Boehringer Ingelheim International GmbH reported $41,126,339.13 across all CMS Open Payments tracks (General + Research + Ownership) to 2,203 physicians and teaching hospitals in Program Year 2024 - ranking #56 of 1,925 reporting manufacturers (0.3% of the all-tracks industry total); General Payments alone were $4,473,810.61, averaging $18.7K per recipient.
How Boehringer Ingelheim International GmbH's $41.1M all-tracks total breaks down
Boehringer Ingelheim International GmbH's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
57/100
Total payments
A
100/100
Transaction volume
F
39/100
Physician reach
F
27/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer boehringer-ingelheim-international-gmbh Boehringer Ingelheim International GmbH
$41.1M · #56/1,925 · 0.3% industry · PY2024
- TOT $41.1M
- RANK #56
- SHARE 0.3%
- TXN 4,047
- RCP 2,203
- CAT 5
- GEN $4.5M
- ΔGEN −$366.1K
- TOP1 16.2%
- PY 2024
Volume peers
Nearest volume peer: Spinal Simplicity, LLC ($40.8M)
Boehringer Ingelheim International GmbH sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Boehringer Ingelheim International GmbH's CMS-reported General Payments decreased by $366.1K (−7.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: BOEHRINGER INGELHEIM INTERNATIONAL GMBHPY2023: BOEHRINGER INGELHEIM INTERNATIONAL GMBHPY2024: Boehringer Ingelheim International GmbH. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $4,839,869.42
- PY2024
- $4,473,810.61
What the Data Shows for Boehringer Ingelheim International GmbH
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Boehringer Ingelheim International GmbH, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 5-category general-payment breakdown below at $1.8M (40.1% of General Payments, 557 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 5 types of general payments, Boehringer Ingelheim International GmbH's largest category was "Consulting Fee" at $1.8M - 40.1% of General Payments.
Boehringer Ingelheim International GmbH reports 5 general-payment categories - the top three are Consulting Fee (40.1%), Grant (31.1%), and Travel and Lodging (16.1%). The remaining 2 categories make up 12.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Boehringer Ingelheim International GmbH divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $1.8M | 557 | 40.1% |
| Grant | $1.4M | 11 | 31.1% |
| Travel and Lodging | $719.5K | 442 | 16.1% |
| Compensation for Services Other Than Consulting | $551.6K | 793 | 12.3% |
| Food and Beverage | $18.8K | 400 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,586,255.48 (35.5%) of $4,473,810.61 in this company's General Payments records across 352 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Boehringer Ingelheim International GmbH
The five named recipients with the highest reported General Payments from this company
- 1
Dana-Farber Cancer Institute
$724,251.13 across 4 reported transactions
- 2
Mount Sinai Medical Center Of Florid
$379,000.00 across 4 reported transactions
- 3
Massachusetts General Hospital
$288,249.75 across 3 reported transactions
- 4
Biykem Bozkurt
$97,867.64 across 32 reported transactions
- 5
Charles Clifton Wykoff
$96,886.96 across 11 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Boehringer Ingelheim International GmbH ranks #56 of 1,925 by total payments (top 3% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,360 of 1,838 by HHI (bottom 26% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- 3-D Matrix, Inc. : $51.0K total payments, HHI 427
- Fisher Scientific Company L.L.C. : $185.9K total payments, HHI 424
- Becton, Dickinson and Company : $7.8M total payments, HHI 423
- DentalEZ, Inc. : $20.1K total payments, HHI 422
- Evoke Pharma, Inc. : $292.8K total payments, HHI 422
- Otsuka Pharmaceutical Development & Commercialization, Inc. : $3.5M total payments, HHI 421
- Boehringer Ingelheim International GmbH (this company) : $4.5M total payments, HHI 421
- Music City Medical Technologies, LLC : $11.8K total payments, HHI 420
- Reel Surgical, Inc. : $22.5K total payments, HHI 417
- Brainsway USA INC : $36.9K total payments, HHI 416
- Erbe USA Inc : $161.0K total payments, HHI 415
- OsteoCentric Technologies, Inc. : $303.4K total payments, HHI 412
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Boehringer Ingelheim International GmbH's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Boehringer Ingelheim International GmbH.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Boehringer Ingelheim International GmbH.
Showing 6 of 1,924 companies with CMS-reported payment data.
Sanofi Pasteur Inc.
$42.5M 14,446 recipients
Compare payment profiles
Alnylam Pharmaceuticals Inc.
$39.2M 19,104 recipients
Compare payment profiles
ViiV Healthcare Company
$38.7M 65,891 recipients
Compare payment profiles
Exelixis Inc.
$37.1M 10,612 recipients
Compare payment profiles
Daiichi Sankyo Inc.
$45.4M 55,658 recipients
Compare payment profiles
Put this to use
Boehringer Ingelheim International GmbH ranks #56 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Boehringer Ingelheim International GmbH sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Boehringer Ingelheim International GmbH. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.